

Escaping from flatland: substituted bridged pyrrolidine fragments with inherent three-dimensional character

Article (Accepted Version)

Cox, Brian, Zdorichenko, Victor, Cox, Philip B, Booker-Milburn, Kevin I, Paumier, Romain, Elliott, Luke D, Robertson-Ralph, Michael and Bloomfield, Graham (2020) Escaping from flatland: substituted bridged pyrrolidine fragments with inherent three-dimensional character. ACS Medicinal Chemistry Letters, 11 (6). pp. 1185-1190. ISSN 1948-5875

This version is available from Sussex Research Online: <http://sro.sussex.ac.uk/id/eprint/91031/>

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

Copyright and reuse:

Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Escaping from Flatland: Substituted Bridged Pyrrolidine Fragments with Inherent Three-dimensional Character.

Brian Cox,^{*,†,‡} Victor Zdorichenko,[‡] Philip B. Cox,^{*,†,¶} Kevin I. Booker-Milburn,^{§,#} Romain Paumier,[‡] Luke D. Elliott,[§] Michael Robertson-Ralph,[#] and Graham Bloomfield[†]

[†]School of Life Sciences, University of Sussex, Brighton, BN1 9QJ, U.K.

[‡]Photodiversity Ltd, c/o School of Life Sciences, University of Sussex, Brighton, BN1 9QJ, U.K.

[§]School of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, U.K.

[#]Photodiversity Ltd, c/o School of Chemistry, University of Bristol, Cantock's Close, Bristol, BS8 1TS, U.K.

[¶]Drug Discovery Science and Technology, AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064-6217, U.S.A.

KEYWORDS: Drug discovery, photochemistry, sp^3 rich scaffolds, substituted bridged pyrrolidine fragments, 3D character.

ABSTRACT: The pressure to deliver new medicines to the patient continues to grow along with increases in compound failure rate; thus, putting the current R&D model at risk. Analysis has shown that increasing the three-dimensionality of potential drug candidates decreases the risk of failure and improves binding selectivity and frequency. For this reason many workers have taken a new look at the power of photochemistry, as a means to generate novel sp^3 rich scaffolds for use in drug discovery programs. Here we report the design, synthesis and computational structural analysis of a series of 2,4-methanoprolines having inherent 3D character (PMI and PBF Scores) significantly higher than that of the broader AbbVie Rule of 3 collection.

In their seminal paper entitled “*Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success*” Lovering *et al* hypothesized that the shift to high-throughput synthetic practices had resulted in more alicyclic, aromatic compounds.¹ This was supported by Walters *et al* who analysed the types of molecules that had been made by medicinal chemists over the 50 years preceding 2009. It showed quite conclusively the dramatic rise in the proportion of molecules containing sp^2 - sp^2 couplings. The authors attributed this trend away from sp^3 character to the introduction of new methods for sp^2 - sp^2 couplings, and the adaptation of these methods to high-throughput synthesis, utilised widely in optimisation programs and in archive “enrichment” campaigns (Figure 1).²

Lovering *et al* focussed on carbon bond saturation as defined by fraction sp^3 (F_{sp^3}) where $F_{sp^3} = (\text{number of } sp^3 \text{ hybridized carbons} / \text{total carbon count})$ as a simple and interpretable measurement of the complexity of molecules prepared as potential drug candidates. They went on to demonstrate that complexity (as measured by F_{sp^3}) correlates with success as compounds transition from discovery, through clinical testing, to drugs (see Figure 2). They further demonstrated that saturation correlates with solubility, an experimental physical property important to success in the drug discovery setting.¹

In a later paper, Lovering described how increasing complexity reduces promiscuity and Cyp450 inhibition. In-

creased promiscuity has been linked to toxicity and candidate failure.³




Figure 1. Influence of sp^2 - sp^2 coupling chemistries on the molecules published in the Journal of Medicinal Chemistry between 1959 and 2009. Data are shown as the fraction of molecules published in each 5-year period containing at least one acyclic-aromatic carbon-carbon bond. Reprinted from ref (2). Copyright 2011, American Chemical Society.





Figure 2. Mean Fsp³ for compounds in different stages of development. ***P* value <0.001. Reprinted from ref (1). Copyright 2009, American Chemical Society.

Further to the positive impact of increasing fraction sp³ (Fsp³) on attrition rates, Clemons *et al* examined compounds from different sources (commercial, academic, natural) for their protein-binding behaviours and found that these behaviours correlate with general trends in stereochemical and shape descriptors for these compound collections. Increasing the content of sp³-hybridized and stereogenic atoms relative to compounds from commercial sources, which comprise the majority of current screening collections, improved binding selectivity and frequency.⁴

A well-established approach to the generation of high quality small molecular weight leads for drug discovery programs is by the application of fragment based methods. We were prompted to look at synthetic methodologies that could be utilised to efficiently generate novel, complex, sp³ rich fragments. For a number of years, we have been investigating the use of photochemistry, in particular [2+2] cycloadditions, as a source of desirable starting points for medicinal chemistry.⁵ We have, like other workers, focussed some of our efforts on analogues of 2,4-methanoproline **1**. 2,4-methanoproline **1** was first isolated from the seeds of *Ateleia herbert smithii* Pittier, a tree found in Costa Rica,⁶ and is prepared in a simple sequence of reactions from ethyl pyruvate **2** or serine **3** (Scheme 1) via intramolecular [2 + 2] olefin photocycloaddition reactions.^{7,8} The utility and conformational properties of 2,4-methanoproline **1** as a replacement for D- or L-proline has been studied, its *N*-acetyl, methyl ester was found to show a large prevalence for a *trans*-amide conformation more akin to primary amino acids than to D- or L-proline.⁹ This makes it a potentially interesting amino acid for inclusion in therapeutic peptides and the basis for the design of fragment libraries. A number of 2-position variants of 2,4-methanoproline have been reported recently¹⁰ and a small number of 4-substituted analogues, such as the 4-methyl **4** and 4-fluoro **5** derivatives (Figure 3).⁹ We embarked on the synthesis of novel 2-substituted and 2,4-substituted analogues of interest in their own right but which were further utilised to prepare diverse *N*-substituted amide and urea parallel libraries with a view to exploring their utility as fragments in a screening library. The compounds were designed to examine the three-dimensional molecular shape and vectors produced by extended substituents at the *N*-1, 2 and 4-positions.

Scheme 1. Synthesis of 2,4-methanoproline **1**



Reagents and conditions: (a) Allylamine then AcCl, Et₃N, benzene (22%); (b) *hν*, acetone (55%); (c) Aq. KOH (72%); (d) PhCOCl, Et₃N, DCM, then NaH, allyl Br, DMF (80%); (e) *hν*, acetophenone, MeCN (88%); (f) 6 N HCl (99%).





Figure 3. 4-Substituted 2,4-methanoproline analogues

***N*-1, 2-substituent variations.** The *N*-benzoyl, ethyl ester of 2,4-methanoproline **6** was prepared by the method of Malpass *et al.*¹¹ This compound was used to prepare a diverse range of proline derivatives; the 2-hydroxymethyl **7**, the 2-methoxymethyl **8** and the 2-carboxamido **9** analogues (Scheme 2), from which a novel array of *N*-substituted amides and ureas were prepared using parallel synthesis methods (Table 1).





























Scheme 2. Synthesis of 2-substituent variations of 2,4-methanoproline.








Reagents and conditions: (a) LiAlH₄, THF (78%); (b) Ammonium formate, Pd/C, EtOH (94%); (c) DIPEA, HATU, DCM, R₁ amine (See Table 1 for yields); (d) 6 N HCl (76%); (e) NaH, MeI, THF (81%); (f) Ammonium formate, Pd/C, EtOH (92%); (g) 4-Isocyanopyridine, DCM (39%); (h) CbzCl, aq. Na₂CO₃, (80%); (i) Aq. Ammonia, HATU DIPEA,

DCM (80%); (j) Ammonium formate, Pd/C, EtOH (90%); (k) 2-Fluorobenzyl isocyanate, DCM (44%).


Table 1. *N*-1 Amide derivatives of 2-substituent variations of 2,4-methanoproline.

 Compound number (Yield%)	 Compound number (Yield%)	 Compound number (Yield%)
 10 (59%)	 21 (49%)	 29 (60%)
 11 (31%)	 22 (40%)	 30 (70%)
 12 (47%)	 23 (65%)	 31 (33%)
 13 (62%)	 24 (50%)	 32 (32%)
 14 (54%)	 25 (54%)	 33 (56%)
 15 (51%)	 26 (63%)	 34 (62%)
 16 (42%)	 27 (61%)	 35 (64%)
 17 (56%)		 36 (71%)
 18 (60%)		 37 (74%)

 19 (33%)		 38 (36%)
 20 (47%)		 39 (29%)
		 40 (43%)




















***N*-1, 2,4-substituent variations.** The 4-carboxylic acid derivative of 2,4-methanoproline was prepared as its *N*-benzoyl, 4-ethyl, 2-methyl diester **42** by the method of Esslinger *et al.*¹² This compound was used to prepare the 4-fluoromethyl derivative **43** and the 4-fluoromethyl-2-hydroxymethyl derivative **44** (Scheme 3), from which a further novel array of *N*-substituted amides were prepared using parallel synthesis methods (Table 2). This sequence involved the selective saponification of the 4-ethyl ester in the presence of the 2-methyl ester using lithium hydroxide in a THF water mixture, followed by selective reduction of the carboxylic acid function and fluorination of the alcohol product.

Scheme 3. Synthesis of 2,4-substituent variations of 2,4-methanoproline.



Reagents and conditions: (a) LiOH, THF/H₂O (84%); (b) BH₃THF, THF (84%); (c) DAST, DCM (68%); (d) TFA, H₂O (43%); (e) DIPEA, HATU, DCM, R₁ amine (See Table 2 for yields); (f) LiAlH₄, THF then Ammonium formate, Pd/C, EtOH (40%).

Table 2. *N*-1 Amide derivatives of 2,4-substituent variations of 2,4-methanoproline.

 <p>Compound number (Yield%)</p> <p>45 (44%)</p>	 <p>Compound number (Yield%)</p> <p>54 (48%)</p>
 <p>46 (50%)</p>	 <p>55 (48%)</p>
 <p>47 (38%)</p>	 <p>56 (47%)</p>
 <p>48 (49%)</p>	 <p>57 (50%)</p>
 <p>49 (45%)</p>	 <p>58 (35%)</p>
 <p>50 (24%)</p>	 <p>59 (49%)</p>
 <p>51 (45%)</p>	 <p>60 (45%)</p>
 <p>52 (28%)</p>	 <p>61 (59%)</p>
 <p>53 (34%)</p>	 <p>62 (37%)</p>
	 <p>63 (41%)</p>

Computational Analysis

In order to investigate the in-silico properties of these molecules, the structures were uploaded into AbbVie's design platform. In addition to a range of physicochemical properties, the Principal Moments of Inertia (PMI) and the Plane of Best Fit (PBF) scores were calculated using methods described in the literature.^{13,14} These descriptors were

then used in combination to map the 3-dimensional space of these compounds. Plotting the sum of the normalized PMIs versus the PBF score, the compounds within the region of the graph defined by ΣNPR (Sum of the Normalized Principal Moments of Inertia (NPR1 and NPR2)) ≥ 1.07 and PBF Score ≥ 0.6 are deemed, by Firth *et al*, to reside in 3D space by virtue of two independent 3D descriptors. Figure 4 shows this plot for 54 of the bridged pyrrolidines, with the corresponding unfunctionalized methanoproline intermediates labelled. Note that the shape was assigned using an approximation based on the relative values of NPR1 and NPR2.




Figure 4. Plot of the normalized PMI versus PBF score for all 54 fragments.

All but 5 of these fragments sit in 3D space with all of the intermediates resting comfortably in this region of space. A comparison of the relative level of 3-dimensionality with other fragments within the AbbVie Ro3 fragment collection is shown in Figure 5.




Figure 5. The % of compounds in 3D space for AbbVie's Ro3 fragment library vs bridged pyrrolidines.

Overall the % of 3D character of the bridged pyrrolidines is significantly higher (91%) than that of the broader AbbVie Rule of 3 (Ro3) collection (58%) which is testament to the proclivity of this scaffold to produce compounds with a higher degree of 3D character within Ro3 chemical space. This is similar to pyrrolidines which are common scaffolds in drugs and known to enhance the 3D nature of fragments, with enabling chemistries employed to maximize both 2 and especially 3D diversity of fragment space.¹⁵ It is interesting to note that the unsubstituted methanoproline intermediates are highly saturated with proportionate levels of F_{sp^3} , however for the majority of the corresponding substituted amide products, the level of 3 dimensionality increases as the level of saturation decreases.




Figure 6. Comparison of F_{sp^3} versus PBF score for the methanoproline (compound 7) derived series.

As an example, we analysed the series of compounds from the methanoproline derivative (compound 7) and plotted F_{sp^3} versus PBF score. While the unsubstituted proline is fully saturated ($F_{sp^3}=1$), the corresponding amide products have lower levels of saturation ($F_{sp^3}<1$), however in many cases they possess higher degrees of 3-dimensionality (see Figure 5). The 3D structures of the corresponding conformations used to calculate the 3D descriptors were visualized using Cresset's Forge™ platform. It was evident from these 3D structures why compound 19 possessed a higher degree of 3D character with a sphere-like conformation, while compound 13 is a flatter, more rod-like shape. This demonstrates that F_{sp^3} should be used with caution when describing the relative 3-dimensionality of compounds. Overall these bridged pyrrolidines possess inherent 3D character and allow for the addition of fragments with higher degrees of favorable 3-dimensionality. In addition, this method opens the door to prospective tailoring of the 3D character of the fragment library prior to synthesis.

Conclusion. Over the coming 5-10 years the predicted positive impact of researchers synthesizing compounds with higher F_{sp^3} in drug discovery programs will become further apparent. Photocycloaddition reactions stand to play a significant part in generating highly desirable templates such as the 2,4-methanoproline derivatives covered here. Our computational analysis clearly demonstrates that fragments derived from 2,4-methanoproline have inherent 3D character using two independent 3D descriptors (PMI and PBF Score) and that the degree of shape and 3D character may be prospectively designed and biased towards fragments with enhanced 3D character, residing in distinct property space to that largely occupied by conventional screening libraries, thus enabling the “escape from flatland”.

ASSOCIATED CONTENT

Supporting Information

The supporting information is available free of charge on the ACS Publications website at DOI:

Synthetic methods, characterization, crystallographic and computational modeling data.

AUTHOR INFORMATION

Corresponding Author

* E-mail: b.cox@sussex.ac.uk or contact@photodiversity.uk.com

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare the following competing financial interest(s): PBC is an employee of AbbVie. BC and KIBM are employees of their respective universities, co-founders and owners of Photodiversity Ltd. The design, study content, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.

Funding Sources

We gratefully acknowledge support for Luke Elliott from the Engineering and Physical Sciences Research Council (EP/P013341/1).

ACKNOWLEDGMENTS

The authors wish to thank the following colleagues for providing small molecule analysis data. Dr Alaa Abdul-Sada (high resolution mass spectrometry), Dr Iain Day (NMR) and Dr Mark Roe (X-ray crystallography). We are also grateful to the Universities of Sussex and Bristol.

ABBREVIATIONS

DAST, Diethylaminosulfur trifluoride; DCM, dichloromethane; DMF, Dimethylformamide; DIPEA, diisopropylethylamine; HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate; THF, tetrahydrofuran.

REFERENCES

- (1) Lovering, F.; Bikker, J.; Humble, C. Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success. *J. Med. Chem.* **2009**, *52*, 6752-6756.
- (2) Walters, W. P.; Green, J.; Weiss, J. R.; Murcko, M. A. What do medicinal chemists actually make? A 50-year retrospective. *J. Med. Chem.* **2011**, *54*, 6405-6416.
- (3) Lovering, F. Escape from Flatland 2: complexity and promiscuity. *Med. Chem. Commun.* **2013**, *4*, 515-519.
- (4) Clemons, P. A.; Bodycombe, N. A.; Carrinski, H. A.; Wilson, J. A.; Shamji, A. F.; Wagner, B. K.; Koehler, A. N.; Schreiber, S. L. Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles. *Proc. Natl. Acad. Sci. U. S. A.*, **2010**, *107*, 18787-18792.
- (5) Cox, B.; Booker-Milburn, K. I.; Elliott, L. D.; Robertson-Ralph, M.; Zdorichenko, V. Escaping from Flatland: [2 + 2] Photocycloaddition; Conformationally Constrained sp³-rich Scaffolds for Lead Generation. *ACS Med. Chem. Lett.* **2019**, *10*, 1512-1517.
- (6) Bell, E. A.; Qureshi, M. Y.; Pryce, R. J.; Jansen, D. H.; Lemke P.; Clardy, J. 2,4-Methanoproline (2-Carboxy-2,4-methanopyrrolidine) and 2,4-Methanoglutamic Acid (1 - Amino-1,3-dicarboxycyclobutane) in Seeds of *Ateleia Herbert smithii* Pittier (Leguminosae) *J. Am. Chem. Soc.* **1980**, *102*, 1409-1412.
- (7) Pirrung, M. C. Total Synthesis of 2,4-Methanoproline *Tetrahedron Lett.* **1980**, *21*, 4577-4578.
- (8) Varnes, J. G.; Lehr, G. S.; Moore, G. L.; Hulsizer, J. M.; Albert, J. S. Efficient preparation of 2,4-methanoproline. *Tetrahedron Lett.* **2010**, *51*, 3756-3758.
- (9) Mykhailiuk, P. K.; Kubyshkin, V.; Bach, T.; Budisa, N. Peptidyl-Prolyl Model Study: How Does the Electronic Effect Influence the Amide Bond Conformation? *J. Org. Chem.* **2017**, *82*, 8831-8841.
- (10) Levterov, V. V.; Michurin, O.; Borysko, P. O.; Zozulya, S.; Sadkova, I. V.; Tolmachev, A. A.; Mykhailiuk, P. K. Photochemical In-Flow Synthesis of 2,4-Methanopyrrolidines: Pyrrolidine Analogues with Improved Water Solubility and Reduced Lipophilicity. *J. Org. Chem.* **2018**, *83*, 14350-14361.
- (11) Malpass, J. R.; Patel, A. B.; Davies, J. W.; Fulford, S. Y. Modification of 1-substituents in the 2-azabicyclo[2.1.1]hexane ring system; approaches to potential nicotinic acetylcholine receptor ligands from 2,4-methanoproline derivatives. *J. Org. Chem.* **2003**, *68*, 9348-9355.
- (12) Esslinger, C. S.; Koch, H. P.; Kavanaugh, M. P.; Philips, D. P.; Chamberlin, A. R.; Thompson C. M.; Bridges, R. J. Structural Determinants of Substrates and Inhibitors: Probing Glutamate Transporters with 2,4-Methanopyrrolidine-2,4-dicarboxylate. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 3101-3106.
- (13) Firth, N. C.; Brown, N.; Blagg, J. Plane of Best Fit: A Novel Method to Characterize the Three-Dimensionality of Molecules *J. Chem. Inf. Model.* **2012**, *52*, 2516-2525.
- (14) Saurer, W. H. B.; Schwarz, M. K. Molecular Shape Diversity of Combinatorial Libraries: A Prerequisite for Broad Bioactivity *J. Chem. Inf. Comput. Sci.* **2003**, *43*, 987-1003.
- (15) Garner, P.; Cox, P. B.; Rathayake, U.; Holloran, N.; Erdman, P. Design and Synthesis of Pyrrolidine-based Fragments That Sample Three-dimensional Molecular Space. *ACS Med. Chem. Lett.* **2019**, *10*, 811-815.

Insert Table of Contents artwork here

